James Greenfield
Family Medicine · Frackville, PANPI 1396700845
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.7% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2022 at $8,691 and has fallen 78.6% since, to $1,856 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 615 payments — averaging $32.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- AstraZeneca$2K
- GSK$1K
- Lilly USA, LLC$699
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$632
- Teva Pharmaceuticals USA, Inc.$419
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$8,40041%
- Travel & lodging$1,3537%
- Food & beverage$10,49552%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 150 | $12,523 |
| AstraZeneca | 83 | $1,586 |
| GSK | 65 | $1,102 |
| Lilly USA, LLC | 50 | $699 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $632 |
| Teva Pharmaceuticals USA, Inc. | 21 | $419 |
| Braeburn Inc. | 24 | $358 |
| Alkermes, Inc. | 17 | $346 |
| Indivior Inc. | 17 | $308 |
| Neurocrine Biosciences, Inc. | 13 | $297 |
| Otsuka America Pharmaceutical, Inc. | 17 | $288 |
| Amgen | 16 | $257 |
| Johnson & Johnson | 15 | $244 |
| Exact Sciences | 9 | $170 |
| Novo Nordisk | 8 | $152 |
| Boehringer Ingelheim | 10 | $130 |
| E.r. Squibb & Sons, L.L.C. | 5 | $117 |
| Axsome Therapeutics, Inc. | 4 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Verona Pharma, Inc. | 2 | $53 |
| Gilead | 4 | $51 |
| Astellas Pharma US Inc | 2 | $51 |
| Medtronic(2 entities) | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| Lundbeck LLC | 2 | $36 |
| Philips North America LLC | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $29 |
| Pfizer | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,290 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 73 | $108,721 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $84,183 |
| FarxigaDapagliflozin Propanediol | 57 | $74,650 |
| TrulicityDulaglutide | 61 | $72,979 |
| OzempicSemaglutide | 44 | $61,223 |
| EliquisApixaban | 43 | $40,240 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $31,820 |
| OxycontinOxycodone Hcl | 12 | $10,876 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $10,568 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 75 | $10,055 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $6,455 |
| Novolog FlexpenInsulin Aspart | 39 | $5,240 |
| Sucralfate | 12 | $4,568 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,399 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $4,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $130 | $108,72173 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,586 | $106,47196 claims |
| GSKTrelegy Ellipta | $1,102 | $84,183110 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $699 | $73,89384 claims |
| Novo NordiskOzempic | $152 | $61,22344 claims |
| PfizerEliquis | $29 | $40,24043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Frackville
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.